{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T19:19:48Z","timestamp":1793992788078,"version":"4.8.0"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>This study aimed to evaluate the efficacy and safety of non-benzodiazepine hypnotics in the treatment of myasthenia gravis (MG) patients with insomnia.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This is a prospective longitudinal study. Outpatients who met the criteria for stable MG and insomnia diagnosis according to the International Classification of Sleep Disorders (third edition) were included in the study. They took a regular dose of non-benzodiazepine hypnotics (zolpidem 10 mg per night or zopiclone 7.5 mg per night) based on their own preferences. Patients received psychotherapy (including sleep health education) and were followed up for 4\u20135 weeks. Cases with lung diseases, respiratory disorders, or inappropriate use of hypnotic medications were excluded. The primary outcome is the difference in total Pittsburgh Sleep Quality Index (PSQI) score between baseline and the end of follow-up period. Secondary outcomes include the difference in Myasthenia Gravis Activities of Daily Living (MG-ADL) score, 7-item Generalized Anxiety Disorder Questionnaire (GAD-7), and the Patient Health Questionnaire-9 (PHQ-9) between baseline and the end of follow-up period and the safety of medication.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 75 MG patients with insomnia were included in this study. After 4\u20135 weeks of treatment, the total PSQI score and MG-ADL score were lower than baseline (<jats:italic>p<\/jats:italic> &amp;lt; 0.01). No patients had an increased MG-ADL score. The incidence rate of adverse events was 16.0% (12 cases), including dizziness (6 cases, 8.0%), drowsiness (3 cases, 4.0%), fatigue (2 cases, 2.7%), and nausea (1 case, 1.3%), all of which were mild. No patients had new onset breathing disorders.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Non-benzodiazepine hypnotics are safe and effective for stable MG patients who need insomnia treatment.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fneur.2023.1266862","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T16:43:07Z","timestamp":1695400987000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Treatment of insomnia in myasthenia gravis\u2014A prospective study on non-benzodiazepine hypnotics in the treatment of myasthenia gravis patients with insomnia"],"prefix":"10.3389","volume":"14","author":[{"given":"Jingwen","family":"Yan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minhui","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Ke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangyu","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiayu","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianqian","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhu","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuzhou","family":"Guan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liying","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"B1","first-page":"934","article-title":"Chinese guidelines for the diagnosis and treatment of myasthenia gravis 2015","volume":"48","year":"2015","journal-title":"Chin J Neurol"},{"key":"B2","first-page":"3176","article-title":"Analysis of the incidence of depression, anxiety and insomnia and their associated factors in patients with myasthenia gravis","volume":"90","author":"Huiyu","year":"2010","journal-title":"Chin Med J."},{"key":"B3","article-title":"Analysis of sleep quality and influencing factors in patients with myasthenia gravis","author":"Wang","year":"2019","journal-title":"Chin Gen Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1176\/appi.neuropsych.18120383","article-title":"Management of insomnia and anxiety in myasthenia gravis","volume":"31","author":"Jordan","year":"2019","journal-title":"J Neurops Clin Neurosci"},{"key":"B5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/BF01244995","article-title":"Effect of diazepam on muscle weakness in a model of myasthenia gravis in rats","volume":"93","author":"Molenaar","year":"1993","journal-title":"J Neural Transm Gen Sect"},{"key":"B6","doi-asserted-by":"publisher","first-page":"925","DOI":"10.4088\/PCC.21cr02925","article-title":"Management of acute insomnia and anxiety in a patient with myasthenia gravis and respiratory failure","volume":"24","author":"Benjelloun","year":"2022","journal-title":"Care Companion CNS Disord"},{"key":"B7","author":"Wei","year":"2015","journal-title":"Simultaneous Determination of Non-benzodiazepine Sedative-Hypnotics in Biological Samples by Ultra Performance Liquid Chromatography-Mass Spectrometry"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.1378\/chest.14-0970","article-title":"International classification of sleep disorders-third edition: highlights and modifications","volume":"146","author":"Sateia","year":"2014","journal-title":"Chest"},{"key":"B9","first-page":"103","article-title":"Reliability and validity of the Pittsburgh Sleep Quality Index","volume":"29","author":"Liu","year":"1996","journal-title":"Chin J Psychiatry"},{"key":"B10","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1016\/S0022-3999(02)00330-6","article-title":"Test-retest reliability and validity of the Pittsburgh Sleep Quality Index","volume":"53","author":"Backhaus","year":"2002","journal-title":"J Psychosom Res"},{"key":"B11","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/0165-1781(89)90047-4","article-title":"The Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and research","volume":"28","author":"Buysse","year":"1989","journal-title":"Psychiatry Res."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"B13","first-page":"339","article-title":"Introduction and application of commonly used clinical assessment scales for myasthenia gravis","volume":"27","author":"Yan","year":"2019","journal-title":"Chin Clin Neurosci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"10927","DOI":"10.1001\/archinte.166.10.1092","article-title":"A brief measure for assessing generalized anxiety disorder: the GAD-7","volume":"166","author":"Spitzer","year":"2006","journal-title":"Arch Inter Med"},{"key":"B15","first-page":"193","article-title":"Introduction to the guide to the prevention and treatment of anxiety disorders","volume":"46","author":"Wu","year":"2013","journal-title":"Chin J Psychiatry"},{"key":"B16","first-page":"735","article-title":"Application of generalized anxiety scale in screening for generalized anxiety disorder","volume":"17","author":"Zhou","year":"2018","journal-title":"Chin J Gen Practit"},{"key":"B17","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","article-title":"The PHQ-9: validity of a brief depression severity measure","volume":"16","author":"Kroenke","year":"2001","journal-title":"J Gen Inter Med"},{"key":"B18","first-page":"650","article-title":"The role and examples of the Noah's Assessment Scale in the evaluation of adverse drug reactions","volume":"47","author":"Zheng","year":"2012","journal-title":"Chin J Pharm"},{"key":"B19","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1517\/14728210903171948","article-title":"Emerging drugs for insomnia: new frontiers for old and novel targets","volume":"14","author":"Sullivan","year":"2009","journal-title":"Expert Opin Emerg Drugs"},{"key":"B20","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1177\/0091217419860716","article-title":"Updates in insomnia diagnosis and treatment","volume":"54","author":"Bragg","year":"2019","journal-title":"Int J Psychiatry Med"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1266862\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T16:43:15Z","timestamp":1695400995000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2023.1266862\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":20,"alternative-id":["10.3389\/fneur.2023.1266862"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2023.1266862","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]},"article-number":"1266862"}}